Tirzepatide side effects (Phase 3 data) Nausea: 24-33% of participants (dose-dependent) Diarrhea: 18-23% Vomiting: 8-13% Constipation: 11-17% Discontinuation due to adverse events: 4.3-7.1% Serious adverse events: similar to placebo The difference in discontinuation rates is striking
Research has studied its ability to increase plasma growth hormone and IGF-1 levels through sustained pulsatile release
Phase II needs amino acids and other nutrients, including methionine, cysteine, glutamine, glycine, taurine, magnesium, glutathione, alpha-ketoglutarate, vitamins B5 and B12, vitamin C, folate, and choline
Samples were deproteinized with 150 l of internal standard solution